Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
Poumeaud F, Morisseau M, Cabel L, Gonçalves A, Rivier C, Trédan O, Volant E, Frenel JS, Ladoire S, Jacot W, Jamelot M, Foka Tichoue H, Patsouris A, Teixeira L, Bidard FC, Loirat D, Brunet M, Levy C, Bailleux C, Cabarrou B, Deleuze A, Uwer L, Deluche E, Grellety T, Franchet C, Fiteni F, Bischoff H, Vion R, Pagliuca M, Verret B, Bécourt S, Reverdy T, de Nonneville A, Dalenc F.
Poumeaud F, et al. Among authors: cabel l.
Br J Cancer. 2024 Sep;131(4):702-708. doi: 10.1038/s41416-024-02766-9. Epub 2024 Jun 25.
Br J Cancer. 2024.
PMID: 38918555